Scarica l'app Stockscreener
3.02
1.00%
0.03
Precedente Chiudi:
$2.99
Aprire:
$2.98
Volume 24 ore:
6,933
Relative Volume:
0.09
Capitalizzazione di mercato:
$41.76M
Reddito:
-
Utile/perdita netta:
$-10.31M
Rapporto P/E:
-3.9221
EPS:
-0.77
Flusso di cassa netto:
$-12.65M
1 W Prestazione:
+0.00%
1M Prestazione:
-4.13%
6M Prestazione:
+52.53%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.98
$3.02
Intervallo di 1 settimana:
$2.98
$3.091
Portata 52W:
$1.75
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Nome
Grace Therapeutics Inc
Settore
Industria
Telefono
609-322-1602
Indirizzo
103 CARNEGIE CENTER, PRINCETON
Confronta GRCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
3.02 | 41.35M | 0 | -10.31M | -12.65M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.75 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.73 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.86 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.40 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.15 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-02 | Iniziato | TD Cowen | Buy |
| 2020-09-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-07-06 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2020-01-13 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-08-29 | Iniziato | B. Riley FBR | Buy |
| 2019-07-18 | Iniziato | Oppenheimer | Outperform |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Grace Therapeutics Inc Borsa (GRCE) Ultime notizie
Will Grace Therapeutics Inc. outperform the marketMarket Activity Report & Daily Profit Focused Stock Screening - newser.com
How to read the order book for Grace Therapeutics Inc.Jobs Report & Community Verified Watchlist Alerts - newser.com
Grace Therapeutics Inc. stock prediction for this weekProduct Launch & High Return Trade Opportunity Guides - newser.com
Strategies to average down on Grace Therapeutics Inc.July 2025 WrapUp & Entry Point Strategy Guides - newser.com
Can machine learning forecast Grace Therapeutics Inc. recoveryJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
Multi factor analysis applied to Grace Therapeutics Inc.Weekly Market Report & Weekly Top Gainers Alerts - newser.com
Identifying reversal signals in Grace Therapeutics Inc.Portfolio Value Report & Safe Entry Momentum Tips - newser.com
Ryan Group's Managing Director Dr. Grace Pinto Honoured with the Mahatma Award 2025 for Lifetime Achievement and Business Leadership - Yahoo Finance
What drives Grace Therapeutics Inc stock priceInsider Selling Patterns & Weekly Consultation With Financial Pros - earlytimes.in
What the charts say about Grace Therapeutics Inc. todayStop Loss & AI Driven Price Forecasts - newser.com
How strong is Grace Therapeutics Inc. stock revenue growthSwing Trade & Weekly Top Performers Watchlists - newser.com
Real Estate Expert Grace Frank Shares Home Selling Strategies in HelloNation - Yahoo Finance
Pfizer’s Drug Price Cuts Yield Three-Year Trump Tariff Reprieve - Yahoo Finance
What Analyst Ratings Reveal About Austin Engineering Company Limited’s Future ValueMerger & Acquisition Updates & Receive Monthly Expert Trading Blueprints - earlytimes.in
What Futures Contracts Reveal About Unitech Limiteds Near Term VolatilityLow Beta Stocks & Double Or Triple Profits - earlytimes.in
Is Grace Therapeutics Inc a good long term investmentFlag and Pennant Patterns & Low Risk Investment Tips - earlytimes.in
What analysts say about Grace Therapeutics Inc stockMorning Star Patterns & Free Explosive Wealth Accumulation - earlytimes.in
We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully - Yahoo Finance
Grace Therapeutics presents phase 3 trial results for aSAH treatment By Investing.com - Investing.com Nigeria
Grace Therapeutics presents phase 3 trial results for aSAH treatment - Investing.com India
GRCE Unveils Positive Trial Results for GTx-104 at Montreal Conf - GuruFocus
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presen - GuruFocus
Breakthrough in Brain Hemorrhage Treatment: Grace's GTx-104 Shows Superior Safety Profile in Critical Phase 3 Trial - Stock Titan
Big Money Moves: Can Electra Battery Materials Corporation expand its profit marginsJuly 2025 Fed Impact & Stock Market Timing Techniques - khodrobank.com
Institutional scanner results for Grace Therapeutics Inc.Market Activity Summary & Daily Technical Stock Forecast Reports - newser.com
Risk Report: Is Grace Therapeutics Inc a turnaround storyJuly 2025 Macro Moves & Daily Stock Momentum Reports - خودرو بانک
Is Grace Therapeutics Inc. still worth holding after the dipJuly 2025 Intraday Action & Community Consensus Stock Picks - newser.com
Has Grace Therapeutics Inc. found a price floorPortfolio Growth Summary & Community Shared Stock Ideas - newser.com
Sentiment analysis tools applied to Grace Therapeutics Inc.July 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Using flow based indicators on Grace Therapeutics Inc.Trade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Risk vs reward if holding onto Grace Therapeutics Inc.2025 Volatility Report & Weekly High Momentum Picks - newser.com
RSI Check: Will PennyMac Financial Services Inc stock recover after earningsJuly 2025 Weekly Recap & Reliable Price Action Trade Plans - خودرو بانک
Sell Signal: Will Direct Digital Holdings Inc benefit from rate cuts2025 Market Overview & Long-Term Investment Growth Plans - khodrobank.com
Growth Recap: Does Autohome Inc Depositary Receipt outperform in volatile marketsJuly 2025 Momentum & Long-Term Growth Portfolio Plans - خودرو بانک
Will Grace Therapeutics Inc. announce a stock splitWeekly Trading Summary & Stepwise Entry and Exit Trade Signals - خودرو بانک
Grace Therapeutics receives patent for nimodipine IV dosing regimen By Investing.com - Investing.com Australia
Grace Therapeutics receives patent for nimodipine IV dosing regimen - Investing.com India
Grace Therapeutics Secures New Patent for GTx-104 - TipRanks
Recap Report: Is Grace Therapeutics Inc still a buy after recent gainsQuarterly Trade Summary & Weekly High Return Forecasts - خودرو بانک
Grace Therapeutics Inc Azioni (GRCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.07%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):